Veracyte, Inc.
NASDAQ:VCYTBiotechnology
+$1.83 today
- Market cap
- $2.06B
- Beta
- 1.98
- P/E (TTM)
- 48.0
- EPS (TTM)
- $1.11
Volume 2.45M
Average 1.05M
VCYT Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Veracyte, Inc.NASDAQ: VCYT
Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026
Income tax expense turns negative
Q2 FY2026 income tax expense was -$6.05M, compared with $2.23M a year earlier. Trailing-twelve-month income tax expense was -$5.54M. Over 3 fiscal years it compounded at +140.4% a year.
Context
- Income tax expense amounted to 0.4% of revenue in FY2025, unchanged from a year earlier.
- Income tax expense increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income tax expense holds near -$6.05M or moves back toward the trailing-twelve-month quarterly average of -$1.39M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 1.85M USD
- Year-over-year change
- +15.1%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.85M | +15.1% |
| FY2024 | 2024-12-31 | 1.61M | +172.7% |
| FY2023 | 2023-12-31 | (2.21M) | -1760.2% |
| FY2022 | 2022-12-31 | 133K | +102.2% |
| FY2021 | 2021-12-31 | (6.09M) | — |
Income Tax Expense vs competitors
How VCYT compares with its peers on the latest reported figures
- VCYT's LTM Jun 2026 income tax expense of -$5.54M is the lowest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of -310.4% is the lowest of 8, against a peer median of +40.6%.
- Income tax expense amounts to 1.0% of revenue for VCYT, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $1.1M | +744.6% | — | 0.2% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $194K | +40.6% | — | 0.0% |
| LTM Mar 2026 | $100K | +100.4% | — | 0.0% | |
| LTM Mar 2026 | $30K | +66.7% | -19.3% | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Sep 2026 | -$827K | -170.1% | — | 0.1% | |
| LTM Jun 2026 | -$2.67M | -89.0% | — | 0.3% | |
| LTM Mar 2026 | -$4.82M | -269.2% | — | 1.4% | |
| LTM Jun 2026 | -$5.54M | -310.4% | +140.4% | 1.0% | |
| Peer median (excluding VCYT) | $0 | +40.6% | -19.3% | 0.0% | |
Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 219.51M | 296.54M | 361.05M | 445.76M | 517.15M |
| Cost of Revenue | 74.4M | 101.58M | 112.9M | 147.62M | 157.1M |
| Gross Profit | 145.11M | 194.95M | 248.15M | 298.15M | 360.05M |
| Gross Margin | 66.1% | 65.7% | 68.7% | 66.9% | 69.6% |
| Research & Development | 29.84M | 40.6M | 57.31M | 69.29M | 70.81M |
| Selling, General & Admin | 181.19M | 174.08M | 184.23M | 206.04M | 210.95M |
| Operating Expenses | 227.02M | 236.04M | 333.94M | 282M | 285.9M |
| Depreciation & Amortization | 19.59M | 25.93M | 27.19M | 23.46M | 21.42M |
| EBITDA | (61.82M) | (10.3M) | (49.41M) | 49.21M | 89.62M |
| EBITDA Margin | -28.2% | -3.5% | -13.7% | 11.0% | 17.3% |
| Operating Income | (81.9M) | (41.08M) | (85.8M) | 16.14M | 74.15M |
| Operating Margin | -37.3% | -13.9% | -23.8% | 3.6% | 14.3% |
| Interest Income | 135K | 1.97M | 7.34M | 11.15M | 0 |
| Interest Expense | 241K | 198K | 15K | 2K | 0 |
| Other Income / Expenses | 254K | 4.65M | 9.18M | 9.6M | (5.95M) |
| Income Before Tax | (81.65M) | (36.43M) | (76.61M) | 25.74M | 68.2M |
| Pre-Tax Margin | -37.2% | -12.3% | -21.2% | 5.8% | 13.2% |
| Income Tax Expense | (6.09M) | 133K | (2.21M) | 1.61M | 1.85M |
| Net Income | (75.56M) | (36.56M) | (74.4M) | 24.14M | 66.35M |
| Net Margin | -34.4% | -12.3% | -20.6% | 5.4% | 12.8% |
| EPS (Basic) | (1.11) | (0.51) | (1.02) | 0.32 | 0.84 |
| EPS (Diluted) | (1.11) | (0.51) | (1.02) | 0.31 | 0.82 |
| Weighted Avg Shares | 67.89M | 71.55M | 72.64M | 76.48M | 78.58M |
| Weighted Avg Shares (Diluted) | 67.89M | 71.55M | 72.64M | 78.16M | 80.57M |
Veracyte, Inc.
NASDAQ:VCYT
Intrinsic Alpha fair value
Locked
Current Price
$25.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.